Baseline HOMA IR And Circulating FGF21 Levels Predict NAFLD Improvement In Patients Undergoing A Low Carbohydrate Dietary Intervention For Weight Loss A Prospective Observational Pilot Study

This study examined whether doctors could predict which patients would benefit most from low-carb diets for improving fatty liver disease, a common condition where excess fat builds up in the liver. The researchers followed 65 obese patients through a 90-day weight loss program that started with a very low-calorie ketogenic diet (VLCKD) and then transitioned to a regular low-carb diet.

The scientists measured various health markers before and after the diet intervention, including insulin resistance (how well the body responds to insulin) and levels of a protein called FGF21. They used a scoring system called the hepatic steatosis index (HSI) to track improvements in liver fat without needing invasive procedures.

The key finding was that two baseline blood markers could predict success: patients with higher insulin resistance at the start saw greater liver improvements from the diet, while those with lower FGF21 protein levels also responded better. Interestingly, most health improvements happened during the ketogenic phase, but liver health continued improving even more during the less restrictive low-carb phase that followed.

This research suggests that personalized nutrition approaches could be more effective than one-size-fits-all diets. In clinical practice, doctors could potentially use simple blood tests to identify which patients are most likely to benefit from low-carb interventions for fatty liver disease, allowing for more targeted and effective treatment strategies.